F M Debruyne

1.8k total citations · 1 hit paper
20 papers, 1.5k citations indexed

About

F M Debruyne is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Oncology. According to data from OpenAlex, F M Debruyne has authored 20 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Pulmonary and Respiratory Medicine, 6 papers in Surgery and 5 papers in Oncology. Recurrent topics in F M Debruyne's work include Prostate Cancer Treatment and Research (6 papers), Bladder and Urothelial Cancer Treatments (4 papers) and Hormonal and reproductive studies (4 papers). F M Debruyne is often cited by papers focused on Prostate Cancer Treatment and Research (6 papers), Bladder and Urothelial Cancer Treatments (4 papers) and Hormonal and reproductive studies (4 papers). F M Debruyne collaborates with scholars based in Netherlands. F M Debruyne's co-authors include Herbert F.M. Karthaus, Rainy Umbas, Jack A. Schalken, H. Ewout Schaafsma, William B. Isaacs, P P Bringuier, G.O.N. Oosterhof, Chris van Weel, A.L.M. Lagro‐Janssen and J.A. Witjes and has published in prestigious journals such as The Journal of Urology, European Urology and Family Practice.

In The Last Decade

F M Debruyne

20 papers receiving 1.4k citations

Hit Papers

Expression of the cellular adhesion molecule E-cadherin i... 1992 2026 2003 2014 1992 100 200 300 400 500

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
F M Debruyne Netherlands 12 815 497 313 289 242 20 1.5k
Marcia L. Wills United States 22 698 0.9× 681 1.4× 438 1.4× 317 1.1× 192 0.8× 43 1.6k
John Tsihlias Canada 12 490 0.6× 586 1.2× 472 1.5× 244 0.8× 149 0.6× 14 1.2k
David G. Bostwick United States 13 828 1.0× 1.4k 2.8× 246 0.8× 407 1.4× 413 1.7× 15 1.9k
Frank Christoph Germany 24 944 1.2× 352 0.7× 391 1.2× 437 1.5× 308 1.3× 71 1.7k
Mototsugu Muramaki Japan 22 625 0.8× 582 1.2× 424 1.4× 429 1.5× 235 1.0× 90 1.4k
Prabhakar Rajan United Kingdom 23 815 1.0× 595 1.2× 141 0.5× 179 0.6× 324 1.3× 72 1.5k
Norihito Soga Japan 16 611 0.7× 460 0.9× 277 0.9× 214 0.7× 129 0.5× 68 1.2k
Stefan Zastrow Germany 21 509 0.6× 708 1.4× 290 0.9× 323 1.1× 196 0.8× 57 1.3k
Sakunthala C. Kudahetti United Kingdom 15 491 0.6× 533 1.1× 169 0.5× 179 0.6× 309 1.3× 28 1.0k
Myriam Decaussin‐Petrucci France 24 642 0.8× 326 0.7× 307 1.0× 462 1.6× 399 1.6× 100 1.7k

Countries citing papers authored by F M Debruyne

Since Specialization
Citations

This map shows the geographic impact of F M Debruyne's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by F M Debruyne with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites F M Debruyne more than expected).

Fields of papers citing papers by F M Debruyne

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by F M Debruyne. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by F M Debruyne. The network helps show where F M Debruyne may publish in the future.

Co-authorship network of co-authors of F M Debruyne

This figure shows the co-authorship network connecting the top 25 collaborators of F M Debruyne. A scholar is included among the top collaborators of F M Debruyne based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with F M Debruyne. F M Debruyne is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kiemeney, Lambertus A., et al.. (1999). Kidney cancer mortality in The Netherlands, 1950-94: prediction of a decreasing trend.. PubMed. 4(4). 303–11. 5 indexed citations
2.
Steffens, Martijn G., Jeannette Oosterwijk‐Wakka, Otto C. Boerman, et al.. (1999). Immunohistochemical analysis of tumor antigen saturation following injection of monoclonal antibody G250.. PubMed. 19(2A). 1197–200. 21 indexed citations
3.
Poel, H.G. Van Der, M. E. Boon, E. C. M. Ooms, et al.. (1997). Conventional bladder wash cytology performed by four experts versus quantitative image analysis.. PubMed. 10(10). 976–82. 18 indexed citations
5.
Witjes, Wim P.J., G.O.N. Oosterhof, H. Ewout Schaafsma, & F M Debruyne. (1995). THE VALUE OF NEOADJUVANT THERAPY IN LOCALIZED PROSTATE CANCER. International Journal of Urology. 2(1). 1–5. 5 indexed citations
6.
Vegt, P. D. J., J.A. Witjes, Wim P.J. Witjes, et al.. (1995). Original Articles. The Journal of Urology. 153(3 Pt 2). 929–933. 77 indexed citations
7.
Debruyne, F M, et al.. (1995). Advances and Trendsin Hormonal Therapy forAdvanced Prostate Cancer. European Urology. 28(3). 177–188. 19 indexed citations
8.
Vet, Jacqueline A. M., P P Bringuier, H. Ewout Schaafsma, et al.. (1995). Comparison of P53 protein overexpression with P53 mutation in bladder cancer: clinical and biologic aspects.. PubMed. 73(6). 837–43. 53 indexed citations
9.
Umbas, Rainy, William B. Isaacs, P P Bringuier, et al.. (1994). Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer.. PubMed. 54(14). 3929–33. 445 indexed citations
10.
Rosette, Jean J. de la, et al.. (1994). Retreatment rate after surgical and non-surgical treatments.. PubMed. 386. 597–613. 4 indexed citations
11.
Witjes, Wim P.J., Simon Horenblas, G.O.N. Oosterhof, H. Ewout Schaafsma, & F M Debruyne. (1993). Neoadjuvant Therapy inProstate Cancer - Is It of AnyUse?. European Urology. 24(4). 433–437. 3 indexed citations
12.
Tamimi, Yahya, H.G. Van Der Poel, Rainy Umbas, et al.. (1993). Increased expression of high mobility group protein I(Y) in high grade prostatic cancer determined by in situ hybridization.. PubMed. 53(22). 5512–6. 118 indexed citations
13.
Mulders, Peter F.A., et al.. (1992). Value of Biochemical Markers in the Management of Disseminated Prostatic Cancer. European Urology. 21(1). 2–5. 23 indexed citations
14.
Lagro‐Janssen, A.L.M., et al.. (1992). The Effects of Treatment of Urinary Incontinence in General Practice. Family Practice. 9(3). 284–289. 95 indexed citations
15.
Rosette, Jean J. de la, Herbert F.M. Karthaus, Philip E.V. van Kerrebroeck, T de Boo, & F M Debruyne. (1992). Research in 'Prostatitis Syndromes':The Use of Alfuzosin (a New α(1)-Receptor-Blocking Agent) in Patients Mainly Presenting with Micturition Complaints of an Irritative Nature and Confirmed Urodynamic Abnormalities. European Urology. 22(3). 222–227. 51 indexed citations
16.
Umbas, Rainy, Jack A. Schalken, Herbert F.M. Karthaus, et al.. (1992). Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer.. PubMed. 52(18). 5104–9. 514 indexed citations breakdown →
17.
Boon, M. C., et al.. (1991). Morphometry, densitometry and pattern analysis of plastic-embedded histologic material from urothelial cell carcinoma of the bladder.. PubMed. 13(5). 307–15. 15 indexed citations
18.
Monstrey, Stan, et al.. (1988). Urinary Tract Injuries in Children: Are They Different From Adults?. European Journal of Pediatric Surgery. 43(1). 31–34. 6 indexed citations
19.
Lacquet, L.K., et al.. (1988). [Aggressive surgical treatment of mediastinal and pulmonary metastasis of non-seminomatous testicular tumors].. PubMed. 42(2). 130–2. 1 indexed citations
20.
Kurth, K. H., F M Debruyne, R. Hall, et al.. (1987). Embolization and Postinfarction Nephrectomy in Patients withPrimary Metastatic Renal Adenocarcinoma. European Urology. 13(4). 251–255. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026